
    
      In Phase A of the study, healthy females between 9 and 12 years of age will be randomized
      (4:1) to receive the 3-dose regimen of GARDASIL™ or placebo, and those between 13 and 26
      years old will receive GARDASIL™. In Phase B of the study, participants who received placebo
      in Phase A will have the option to receive the 3-dose regimen of GARDASIL™.
    
  